Schuchmann, M; Kittner, JM; Schlaak, JF et al.
SAFETY, TOLERABILITY AND HEPATITIS C VIRAL KINETICS DURING TREATMENT WITH ALL-TRANS RETINOIC PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH PREVIOUS NON-RESPONSE - RESULTS OF THE ATRACTION STUDYHEPATOLOGY. Bd. 54. 2011 S. 1001A-1001A
Marker-Hermann, E
Science, medical education and promotion of young scholars in internal medicineDEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. Bd. 136. H. 48. 2011 S. 2453-2453
Wehler, TC; Graf, C; Altherr, K et al.
SDF1 beta Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by CD8(+) T-CellsANTICANCER RESEARCH. Bd. 31. H. 9. 2011 S. 2797-2803
Muller, A; Bachmann, E; Linnig, M et al.
Selective PI3K inhibition in wild type and PIK3CA mutated human gastrointestinal cancerONKOLOGIE. Bd. 34. 2011 S. 246-246
Sverdlov, D; Chung, J; Violette, S et al.
SELECTIVE TARGETING OF TGF beta 1 ACTIVATION ON CHOLANGIOCYTES USING alpha V beta 6 INTEGRIN-BLOCKING ANTIBODY INHIBITS ADVANCED BILIARY FIBROSIS IN MDR2-/- MICEHEPATOLOGY. Bd. 54. 2011 S. 737A-737A
Seven, G; Karatayli, SC; Kose, SK et al.
Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and DTURKISH JOURNAL OF GASTROENTEROLOGY. Bd. 22. H. 3. 2011 S. 305-314
Pallav, K; Tariq, S; Leffler, DA et al.
Serum IgA in Celiac Disease: The Unrecognized Importance of Partial IgA DeficiencyGASTROENTEROLOGY. Bd. 140. H. 5. 2011 S. S439-S439
Bauer, S; Schulze-Bergkamen, H; Mayer, F et al.
SHORE: A PHASE I/II STUDY OF RESMINOSTAT, AN ORAL HISTONE DEACETYLASE INHIBITOR (HDACI), IN COMBINATION WITH FOLFIRI AS SECOND-LINE TREATMENT IN K-RAS MUTATED COLORECTAL CANCER (CRC) PATIENTSANNALS OF ONCOLOGY. Bd. 22. 2011 S. v118-v119
Aoqui, C; Chmielewski, S; Eissler, R et al.
Short time of high fat intake increases vascular constriction - possible role of local inflammationJOURNAL OF VASCULAR RESEARCH. Bd. 48. 2011 S. 123-123
Dieterich, D; Asselah, T; Guyader, D et al.
SILEN-C3: TREATMENT FOR 12 OR 24 WEEKS WITH BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTIONHEPATOLOGY. Bd. 54. 2011 S. 378A-378A